Proteostasis Puts Best Face On Unspectacular CF Combo Data

With data showing a lung function and sweat chloride benefit for its proprietary CFTR-modulating triplet, Proteostasis says it’s moving ahead. But analysts and investors are concerned the effects are less than seen with Vertex drugs.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.

More from Clinical Trials

More from R&D